SHANNON, CLARE, IRELAND, February 27, 2026 /EINPresswire.com/ -- Announcing a new publication from Opto-Electronic ...
Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...
Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected ...
CNP-104 improved key cholestasis endpoints at one year, including a composite serum alkaline phosphatase (ALP) and bilirubin biochemical ...
The recent safety update led Kyowa Kirin and Amgen to conclude potential risks may outweigh benefits for patient populations.
Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.
Kyowa Kirin announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 ...
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and ...
As part of its launch, Persevere has acquired the clinical-stage program and related assets for misetionamide (GP-2250) from Geistlich Pharma AG. Misetionamide is a novel, first-in-class dual ...
Helus Pharma (NASDAQ: HELP) is a clinical-stage pharmaceutical company developing treatments for depression and anxiety. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results